Drug Metabolism and Pharmacokinetics of Oxazolo[4,5-c]quinoline Analogs as Novel Interleukin-33 Inhibitors
Pharmaceutics · 03.09.2025 · 17 (9) · 1153
DOI: 10.3390/pharmaceutics17091153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 03.09.2025. Verfasst von Hayoung Jeon und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Korea University, Sejong 30019, Republic of Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Background/Objectives: Interleukin-33 (IL-33) is crucial in immune-mediated diseases like asthma. Targeting the IL-33/ST2 pathway holds therapeutic promise. This study characterized the pharmacokinetics (PK) and metabolism of KB-1517 and KB-1518, new oxazolo[4,5-c]quinoline IL-33 inhibitors.
Methods
PK studies were conducted in male ICR mice following intravenous (IV) and oral (PO) administration. In vitro metabolic stability and metabolite identification were assessed using human and mouse liver S9 fractions supplemented with cofactors (NADPH, UDPGA, PAPS, GSH). Plasma and incubation samples were analyzed using validated LC-MS/MS methods.
Results
KB-1517 exhibited slow absorption/elimination and high apparent oral bioavailability (>100%) post-PO, with an unusually late increase in plasma concentration after IV dosing, hindering terminal parameter calculation. KB-1518 showed low clearance post-IV but suffered from low oral bioavailability (~14%). Both compounds demonstrated high in vitro metabolic stability (t½ > 60 min) in both human and mouse liver S9 fractions. Primary metabolism involved phase I oxidation (N-oxidation and N-demethylation), yielding several metabolites identified in vitro and confirmed in vivo. Some species differences in metabolite profiles were observed.
Conclusions
KB-1517 and KB-1518 are promising, metabolically stable IL-33 inhibitor lead compounds with distinct PK profiles. KB-1517’s complex kinetics suggest potential sustained exposure but require further elucidation. KB-1518’s low oral bioavailability necessitates further optimization. These ADME findings provide a critical foundation for their continued optimization and development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy, Korea University, Sejong 30019, Republic of Korea.
- Azcuris Co., Ltd., 2511 Sejong-ro, Sejong 30019, Republic of Korea.
- Interdisciplinary Major Program in Innovative Pharmaceutical Sciences, Korea University, Sejong 30019, Republic of Korea.
ORCID-Profile: Hayoung Jeon, Youngjoo Byun, Kiho Lee
Förderung
- National Research Foundation of Korea
Zitieren
APA
Jeon, H., Jang, G., Ban, M. A., Son, S. H., Byun, Y., & Lee, K. (2025). Drug Metabolism and Pharmacokinetics of Oxazolo[4,5-c]quinoline Analogs as Novel Interleukin-33 Inhibitors. Pharmaceutics, 17(9), 1153. https://doi.org/10.3390/pharmaceutics17091153
Vancouver
Jeon H, Jang G, Ban MA, Son SH, Byun Y, Lee K. Drug Metabolism and Pharmacokinetics of Oxazolo[4,5-c]quinoline Analogs as Novel Interleukin-33 Inhibitors. Pharmaceutics. 2025;17(9):1153. doi:10.3390/pharmaceutics17091153
BibTeX
@article{Jeon2025,
author = {Jeon, Hayoung and Jang, Geonhee and Ban, Min-A and Son, Sang-Hyun and Byun, Youngjoo and Lee, Kiho},
title = {Drug Metabolism and Pharmacokinetics of Oxazolo[4,5-c]quinoline Analogs as Novel Interleukin-33 Inhibitors},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {9},
pages = {1153},
doi = {10.3390/pharmaceutics17091153}
}
EUVIMED